TYK Medicines (HKSE:02410) Revenue: HK$0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02410 TYK Medicines Inc HKSE:02410
7 GF Score
Price HK$3.52
! 3 Warning Signs
View Full Analysis

What is TYK Medicines Revenue?

TYK Medicines HKSE:02410 -5.76% 7 Revenue is HK$0.00 Mil as of Jun. 2026. GuruFocus rates HKSE:02410 with a GF Score™ of 7/100. The stock has 3 warning signs investors should review.

TYK Medicines's revenue for the three months ended in Jun. 2026 was HK$0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was HK$0.00 Mil. TYK Medicines's Revenue per Share for the three months ended in Jun. 2026 was HK$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was HK$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

TYK Medicines  (HKSE:02410) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

TYK Medicines Revenue Related Terms

TYK Medicines Revenue Historical Data

* Premium members only.

The historical data trend for TYK Medicines's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TYK Medicines Revenue Chart

TYK Medicines Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Revenue
51.45 0.00 0.12 0.00

TYK Medicines Quarterly Data
Dec22 Jun23 Dec23 Jun24 Jun25 Dec25 Jun26
Revenue Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

HKSE:02410 vs VRTX, REGN, MRNA: Revenue Comparison

For the Biotechnology subindustry, TYK Medicines's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TYK Medicines Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TYK Medicines's Revenue distribution charts can be found below:

* The bar in red indicates where TYK Medicines's Revenue falls into.


HKSE:02410
7GF Score
TYK Medicines Inc HKSE:02410
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TYK Medicines Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of HK$0.00 Mil mean?
TYK Medicines (HKSE:02410) has a Revenue of HK$0.00 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on TYK Medicines and its competitors.
Is TYK Medicines' Revenue too high?
TYK Medicines' current Revenue is HK$0.00 Mil. Overall, TYK Medicines has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TYK Medicines' Revenue compare to VRTX and REGN?
TYK Medicines' Revenue of HK$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on TYK Medicines and its competitors. TYK Medicines's current Revenue is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TYK Medicines stock overvalued right now?
TYK Medicines (HKSE:02410) has a current Revenue of HK$0.00 Mil. The current Revenue is HK$0.00 Mil. TYK Medicines' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For TYK Medicines (HKSE:02410), the current Revenue is HK$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TYK Medicines Business Description

Address No.277 Longlan Road, 8th Floor, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai, CHN
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
7GF Score

Get the complete analysis for HKSE:02410

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.52
Price